1st Edition
The Ups and Downs in Drug Design Adventures in Medicinal Chemistry
The Ups and Downs in Drug Design: Adventures in Medicinal Chemistry highlights the necessity for an integrative approach in medicinal chemistry and chemical biology. As medicinal chemistry is not a monolithic science, it is important to emphasize the other various disciplines that are required for successful drug design. This book presents the author’s own personal experience in this field and describes the "ups" and "downs" that come with drug discovery. It is an excellent companion text for graduate and postgraduate students who would like further insight into the parameters of drug design, including the challenges that come with the project.
Key Features
- Illustrates "real-life" examples in medicinal chemistry
- Integrates the use of physical, chemical, and biological concepts that are important in drug design
- Highlights the "ups" and "downs" that come with drug discovery
- Aims to inspire students who may be struggling with the challenges and thought process in drug design
- Intends to be an excellent companion text for graduate and postgraduate students
Acknowledgements
About the Author
Foreword
Introduction
Chapter 1. STRUCTURE-ACTIVITY-RELATIONSHIPS (SAR)
Chapter 2. BRAIN ANTI-TUMOR AGENTS. THE STORY OF SPIROMUSTIN
Chapter 3. PRIVILEGED DRUG SCAFFOLDS. THE STORY OF LC-6 AND PYRIDINOLCARBAMATE.
Chapter 4. CYTIDINE DEAMINASE PART 1. THE CONCEPT OF TRANSITION-STATE INHIBITORS AND THE DISCOVERY OF ZEBULARINE.
Chapter 5. CYTIDINE DEAMINASE PART 2. LESSONS FROM NATURE’S TRANSITION STATE INHIBITORS.
Chapter 6. TIAZOFURIN AND THE HISTORY OF THIAZOLE-4-CARBOXAMIDE ADENIDE DINUCLEOTIDE (TAD).
Chapter 7. THE AIDS ERA: NUCLEOSIDE ANTIRETROVIRAL AGENTS.
Chapter 8. THE AIDS ERA: SYNTHESES OF FLUORONUCLEOSIDES AND THE CLINICAL DEVELOPMENT OF LODENOSINE.
Chapter 9. EXPLORATION OF NOVEL NUCLEOSIDE TEMPLATES IN SEARCH OF ACTIVE ANTI-HIV AND ANTIVIRAL DRUGS.
Chapter 10. 3-DEAZANEPLANOCIN A AND CYCLOPENTENYLCYTOSINE.
Chapter 11. EPIGENETICS AND CANCER: 5-AZA-CYTIDINE AND ZEBULARINE.
Chapter 12. ZEBULARINE AS AN EPIGENETIC ANTICANCER AGENT.
Chapter 13. 3-DEAZANEPLANOCIN A (DZNep) AS AN EPIGENETIC ANTICANCER AGENT.
Chapter 14. BICYCLO[3.1.0]HEXANE NUCLEOSIDES. CHEMISTRY.
Chapter 15. BICYCLO[3.1.0]HEXANE NUCLEOSIDES. BIOLOGY (PART ONE).
Chapter 16. BICYCLO[3.1.0]HEXANE NUCLEOSIDES. BIOLOGY (PART TWO). MORE ON KINASES/POLYMERASES AND DRUG DEVELOPMENT OF N-MCT.
Chapter 17. BICYCLO[3.1.0]HEXANE NUCLEOSIDES. BIOLOGY (PART THREE). INVESTIGATING OF MORE EXOTIC TARGETS.
Chapter 18. BICYCLO[3.1.0]HEXANE NUCLEOSIDES. CHEMICAL VARIATIONS ON A COMMON THEME.
Chapter 19. DIACYLGLYCEROL LACTONES AND PROTEIN KINASE C (PKC). A PHARMACOPHORE-GUIDED APPROACH.
Chapter 20. DIACYLGLYCEROL LACTONES AND PROTEIN KINASE C (PKC). TRANSITION FROM A PHARMACOPHORE GUIDED APPROACH TO A RECEPTOR GUIDED APPROACH.
References
Biography
Dr. Victor E. Marquez After one year of postdoctoral studies at the National Cancer Institute (NCI)/National Institutes of Health (NIH), Dr. Marquez returned to Venezuela as Research Director of Cosmos Laboratories. In 1977, he rejoined the NCI as a Visiting Scientist, and from 1999 to 2009 he was Chief of the Laboratory of Medicinal Chemistry. In 2008, Dr. Marquez was named Maryland Chemist of the Year, and in 2010 he was inducted into the Medicinal Chemistry Hall of Fame. Dr. Marquez retired as Scientist Emeritus after 32 years of service.
The purpose of this book is to describe Dr. Marquez's journey/career in medicinal chemistry in a semi-autobiographical function. As it follows his own personal journey, the "chapters" seem random as they parallel his career path and the work/molecules he studied. It is a rather unique text as a career "summary" for Dr. Marquez.In my opinion as a pharmacy educator, the target audience of this book is primarily colleague medicinal chemists who can relate to the changes in the field over the past four decades. Graduate-level students in this field also may admire the pathway and trials and tribulations of a mentoring medicinal chemist. Based on his longstanding career, Dr. Marquez is a leader in this field and an educator.
This is the first book of this style I have come across in my academic career. As the book is based on Dr. Marquez' personal journal, it is rather unique, but a second edition will not apply.
- Patrick J. McDonnell, PharmD (Temple University School of Pharmacy)
This engaging career history by one of the most accomplished and illustrious chemists to work at the National Cancer Institute (NCI) outside of Washington, DC is well worth the read for professional medicinal chemists. It probes the career path of Victor E. Marquez, in his various long-term projects aimed at finding treatments for cancer, malaria, viral infections, immune disorders and other diseases. Early on, during his graduate studies at the University of Michigan (Ph.D., 1970), he was introduced to compounds that interact directly or indirectly with nucleic acids and maintained that focus throughout his career, recognizing the tremendous potential of this area for future therapeutics. Marquez is currently Scientist Emeritus at NCI and remains active in lecturing and writing. His story is also a personal story from his origins in Venezuela, where his father founded and mother helped manage the most prominent pharmaceutical company in Venezuela, to the US and then back and forth, eventually spending most of his career at NCI.
Important topics covered include mechanism-based design of biologically active molecules, when that was not yet popular in mainstream science, inhibitors of cytidine deaminase, conformational control of transition state mimics for enzyme inhibitors, and phosphate analogues that are resistant to hydrolysis. Although initially met with skepticism, Marquez’s concept of "locking" nucleoside conformation is fully embraced by the medicinal chemistry community and has revolutionized the field of nucleoside structure activity relationships (SAR).
This autobiography is not only a delightful read, it is scientifically informative about the origins of many aspects of nucleic acid chemistry that we now take for granted. This volume can be a model for early-stage researchers of how to successfully advance a career in medicinal chemistry. It’s no wonder that Marquez successfully mentored >40 postdoctoral fellows, many of whom have become well-known academic and pharma scientists. Dr. Marquez also shares behind the scenes vignettes leading to either success or failure of his efforts, often for administrative and non-technical reasons. I recommend it highly to anyone in the drug discovery field.
- Kenneth A. Jacobson, Ph.D. NIDDK, NIH
